Apnimed APMD 深 滬
等待開盤 11-07 09:30:00 美东时间
15.10
+0.940
+6.64%
華盛通- 最 高15.405
- 今 開14.26
- 成交量 22.54万股
- 最 低 14.11
- 昨 收 14.16
- 總市值 6.29亿
- 52周最高 35.29
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 13.88
- 委 比 -10.53%
- 總股本 4163.08万
- 歷史最高 35.29
- 量 比 0.43
- 振 幅 9.15%
- 歷史最低 13.88
- 每 手 1
- 風險率 4.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apnimed, Inc. granted 14 new non-executive employees non-qualified stock options to purchase 331,000 shares under its 2026 Inducement Plan. Each option has an exercise price of $15.40, vesting over four years. The grants align with Nasdaq Listing Rule 5635(c)(4) and were approved by the board on August 21, 2026. Apnimed focuses on developing oral therapies for sleep-related breathing diseases, with AD109 targeting improved oxygenation for OSA pat...
11-05 21:05
Apnimed Inc.收跌6.1%，成交额833.63万美元
11月3日，Apnimed Inc.（APMD）收跌6.1%，报15.4美元，成交额833.63万美元，市值6.41亿美元。 行情数据 • 开盘价：16.55美...
11-03 06:57
瑞思迈 (RMD) 2027财年第一季度业绩电话会：每股收益增长14%，重申业绩指引
瑞思迈2027财年第一季度营收增长6%至14亿美元，非GAAP每股收益增长14%至2.91美元。管理层重申了全年业绩指引。
10-29 23:35
Apnimed Inc.收跌0.21%，成交额337.05万美元
10月27日，Apnimed Inc.（APMD）收跌0.21%，报18.95美元，成交额337.05万美元，市值7.89亿美元。 行情数据 • 开盘价：19...
10-27 05:52
Apnimed Inc.收跌2.66%，成交额418.91万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:56
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
Apnimed, Inc. announced that five abstracts, including data from its Phase 3 program evaluating AD109 for obstructive sleep apnea (OSA), have been accepted for presentation at the CHEST 2026 Annual Meeting in Phoenix. The presentations include late-breaking abstracts on AD109's effects in post-menopausal women and its potential impact on blood pressure, as well as real-world data on OSA's burden. A panel discussion will explore the results of the...
10-12 20:05
Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M
Apnimed (NASDAQ:APMD) reported quarterly earnings of $3.91 per share which beat the analyst consensus estimate of $(0.34) by 1250 percent. The company reported $12.080 million in sales this quarter.
09-09 04:41
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apnimed granted 10 new employees stock options for 428,428 shares at $26.85 per share under its 2026 Inducement Plan. The options vest over four years. Apnimed focuses on developing oral therapies for sleep-related breathing disorders, with its lead candidate AD109 targeting OSA. AD109 has completed Phase 3 trials and has a PDUFA goal date of February 28, 2027.
09-04 20:01
美股大行评级 | 瑞杰金融维持英伟达"强力买入"评级，目标价从330美元升至352美元；瑞穗下调美光科技目标价从1375美元降至1300美元
今日重点评级关注：摩根大通：维持Ultragenyx Pharmaceutical"超配"评级，目标价从75美元升至80美元；瑞杰金融：维持英伟达"强力买入"评级，目标价从330美元升至352美元
08-26 08:37
Apnimed rises on Street initiations following IPO
Apinimed (APMD), which just had its IPO on July 31, is up ~11% in Tuesday morning trading after a pair of new positive Street initiations. BofA Securities started the sleep drug developer off as a buy...
08-25 23:31
